Core Viewpoint - The company has conducted its third quarterly board meeting and approved several key resolutions, including the financial report and the use of idle funds for investment in financial products [8][31][37]. Financial Data - The third quarter financial report has not been audited [7]. - The company plans to apply for a total of 5.7 billion yuan in loans from various banks to support its operational needs [9]. Shareholder Information - The company is addressing issues related to shareholding transparency, particularly concerning the shareholding of Liu Jianming, which is still under a holding arrangement [5]. - The company has developed a rectification plan to resolve the issues of shareholding representation and ensure accurate information disclosure [4]. Governance Changes - The board has approved the cancellation of the supervisory board and amendments to the company’s articles of association, which will be submitted for approval at the upcoming shareholder meeting [10][32]. - Various governance documents and rules have been revised and approved by the board, including those related to shareholder meetings and board operations [12][15][19]. Investment Strategy - The company intends to use up to 50 million yuan of idle funds to purchase financial products, aiming to enhance the efficiency of fund utilization while ensuring operational needs are met [37][43]. - The investment will focus on low-risk, high-liquidity financial products issued by banks and asset management companies [38].

Core Viewpoint - Jilin Province Jichang Yisheng Pharmaceutical Co., Ltd. has decided to abolish its supervisory board and amend its articles of association, with the supervisory board's functions being transferred to the audit committee of the board of directors [1][2]. Group 1: Cancellation of Supervisory Board - The company will no longer have a supervisory board, and its powers will be assumed by the audit committee of the board of directors [1]. - The cancellation of the supervisory board requires approval from the shareholders' meeting, and until then, the current supervisory board will continue to fulfill its duties [2]. - The company expresses gratitude to the current supervisors for their contributions during their tenure [2]. Group 2: Amendments to Articles of Association - The company plans to amend certain provisions of its articles of association in light of the cancellation of the supervisory board [2][3]. - The amendments will be subject to approval by the shareholders' meeting and require a special resolution with at least two-thirds of the voting rights present [2][3]. - The final content of the amendments will be subject to approval by the market supervision administration [2][3]. Group 3: Revision and Formulation of Governance Systems - The company is revising and formulating several governance systems to align with the latest legal and regulatory requirements [3][4]. - Revised documents include the articles of association, rules for shareholder meetings, rules for board meetings, and newly established remuneration management systems for directors and senior management [3][4]. - The revised governance documents will also require approval from the shareholders' meeting before they take effect [4].

Core Points - The company has ensured that the information disclosed is true, accurate, and complete, with no false records or misleading statements [1][2][31] - The third-quarter financial report has not been audited [3][7] - The company plans to apply for a total of 5.7 billion yuan in working capital loans from various banks to purchase raw materials and meet operational needs [9][10] Financial Data - The company has confirmed that there are no adjustments or restatements required for previous accounting data [3] - The third-quarter report was approved unanimously by the board of directors [8][31] - The company will use up to 50 million yuan of idle funds to purchase financial products to improve fund utilization efficiency [37][44] Shareholder Information - The company is addressing issues related to shareholding representation and has implemented a rectification plan to clarify actual shareholding situations [4][5] - The company will hold its first extraordinary general meeting of 2025 on November 12, 2025, to discuss various proposals [47][48] Governance Changes - The board has approved the cancellation of the supervisory board and amendments to the company's articles of association [10][32] - Several governance documents have been revised and approved, including rules for shareholder meetings and board meetings [12][15][19]

Core Viewpoint - Jilin Province Jichang Yisheng Pharmaceutical Co., Ltd. has decided to abolish its supervisory board and amend its articles of association, with the supervisory board's functions being transferred to the audit committee of the board of directors [1][2]. Group 1: Cancellation of Supervisory Board - The company will no longer have a supervisory board, and the powers of the supervisory board will be exercised by the audit committee of the board of directors [1]. - Following the cancellation, the supervisors will automatically resign, and related rules such as the "Supervisory Meeting Rules" will be abolished [1]. - The board of directors will seek authorization from the shareholders' meeting to handle the necessary registration and filing for the cancellation of the supervisory board and the amendments to the articles of association [1]. Group 2: Amendments to Articles of Association - The company plans to amend certain provisions of its articles of association in light of the cancellation of the supervisory board [2]. - The amendments will comply with relevant laws and regulations, including the Company Law of the People's Republic of China and the Shenzhen Stock Exchange Listing Rules [2].

Core Insights - Yisheng Pharmaceutical (002566.SZ) reported a revenue of 476 million yuan for the first three quarters of 2025, representing a year-on-year decline of 5.81% [1] - The company's net profit attributable to shareholders was 24.13 million yuan, down 32.72% year-on-year [1] - The non-recurring net profit was 12.56 million yuan, reflecting a year-on-year decrease of 37.81% [1] - Basic earnings per share stood at 0.0729 yuan [1]

Group 1 - Yisheng Pharmaceutical announced plans to use up to 50 million RMB of idle funds to purchase financial products to improve capital efficiency while ensuring operational needs and fund safety [1] - The funds can be used on a rolling basis within a maximum period of 12 months [1] - As of the report date, Yisheng Pharmaceutical has a market capitalization of 2.7 billion RMB [1] Group 2 - For the first half of 2025, Yisheng Pharmaceutical's revenue composition is as follows: 81.06% from the pharmaceutical industry, 10.27% from health products and others, 7.39% from cosmetics, and 1.28% from other sources [1]

Group 1 - Yisheng Pharmaceutical (SZ 002566) announced on October 26 that its ninth board meeting was held on October 24, 2025, to review proposals regarding the revision and formulation of certain governance systems [1] - For the first half of 2025, Yisheng Pharmaceutical's revenue composition was as follows: 81.06% from the pharmaceutical industry, 10.27% from health products and others, 7.39% from cosmetics, and 1.28% from other sources [1] - As of the report date, Yisheng Pharmaceutical's market capitalization was 2.7 billion yuan [1]

（记者 王晓波） 截至发稿，益盛药业市值为27亿元。 每经AI快讯，益盛药业（SZ 002566，收盘价：8.11元）10月26日晚间发布三季度业绩公告称，2025年 前三季度营收约4.76亿元，同比减少5.81%；归属于上市公司股东的净利润约2413万元，同比减少 32.72%；基本每股收益0.0729元，同比减少32.75%。 每经头条（nbdtoutiao）——金价大"崩盘"：12年来最大单日跌幅背后，四大指标早已预警！后市怎么 走？华尔街吵翻了 ...

吉林省集安益盛药业股份有限公司 (一)为确保独立董事当选人数符合公司章程的规定,独立董事与非独立董事 的选举实行分开投票方式。具体操作如下： 1 累积投票制实施细则 第一条 为了促进吉林省集安益盛药业股份有限公司（以下称"公司"）的 规范运作，维护公司整体利益，保障全体股东特别是中小股东的合法权，规范公 司选举董事行为，根据《中华人民共和国公司法》、中国证券监督管理委员会《上 市公司治理准则》等有关法律、法规和规范性文件以及《吉林省集安益盛药业股 份有限公司公司章程》（以下简称"公司章程"）的有关规定，制定本实施细则。 第二条 本实施细则所指的累积投票制是指公司股东会在选举两名以上的 董事时采用的一种投票方式。即公司股东会选举董事时，股东所持的每一有效表 决权股份拥有与该次股东会应选董事总人数相等的投票权,股东拥有的投票权等 于该股东持有股份数与应选董事总人数的乘积。股东既可以用所有的投票权集中 投票选举一位候选董事，也可以将投票权分散行使,投票给数位候选董事，最后 按得票多少依次决定当选董事。 第三条 股东会选举产生的董事人数及结构应符合公司章程的规定。 第四条 公司一次选举的董事仅为一名时，不适用累积投票 ...

吉林省集安益盛药业股份有限公司 控股子公司管理制度 第一条 为规范公司行为，保证股东依法行使职权，根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司章程指引》、《深圳证券交易所上市公司自律监管指引第1号— —主板上市公司规范运作》、《深圳证券交易所股票上市规则》（以下简称"《股票 上市规则》"）、《上市公司治理准则》和《上市公司股东会规则》以及其他法律、 行政法规和《吉林省集安益盛药业股份有限公司章程》（以下简称"《公司章程》"） 的规定，制定本制度。 第二条 本制度所称"控股子公司"是指公司根据发展战略规划和突出主业、 提高公司核心竞争力需要而依法设立的，具有独立法人资格主体的公司。其设立 形式包括： （一）公司独资设立的全资子公司； （二）公司与其他公司或自然人共同出资设立的，公司控股50%以上（不含 50%），或未达到50%但能够决定其董事会半数以上成员的组成，或者通过协议或 其他安排能够实际控制的公司。 第三条 本制度适用于公司及公司控股子公司。 公司委派至各控股子公司的董事、监事、审计委员会成员、高级管理人员应 该严格执行本制度 ...